In this issue:
Gliadin nanoparticles induce gluten-specific tolerance
Gluten degradation with an engineered enzyme
Outcomes after anti-TNF discontinuation in IBD
Long-term treatment persistence of first anti-TNF therapy
Treatment persistence with biologics in IBD
Postoperative complications with preoperative anti-TNF use
Safety of ustekinumab in IBD
Subcutaneous vs intravenous infliximab biosimilar
Combination therapy with vedolizumab or ustekinumab in IBD
Birth outcomes after paternal exposure to immunosuppressive/biologic agents
Please login below to download this issue (PDF)